Company Profile
LYFE Capital is a leading healthcare investment platform founded in 2015, with a presence across Asia and the United States. The firm is led by seasoned investment veterans and operators who have navigated multiple market cycles. LYFE Capital focuses on investing in critical healthcare supply chain assets, specialized product platforms, and next-generation research and development services, enabling portfolio companies to generate significant and resilient revenues from mature global markets.
The company actively supports a diverse portfolio of healthcare companies, including contract development and manufacturing organizations (CDMOs), surgical robotics, antibody-drug conjugates (ADC), pharmaceutical development, and clinical research organizations (CROs). LYFE Capital leverages its global ecosystem and strategic partnerships to help companies scale operations, expand geographically, and enhance operational efficiency, particularly bridging markets between Asia and the U.S.
With offices in Shanghai, Hong Kong, Seoul, Singapore, and Palo Alto, California, LYFE Capital manages approximately USD 2 billion in assets under management. The firm invests across multiple healthcare sectors, including biotechnology, pharmaceuticals, medical devices, diagnostics, healthcare services, and digital health. LYFE Capital emphasizes ESG principles and supports companies at various stages, primarily focusing on early to growth-stage ventures with established products seeking international expansion.
News & Signals (0)
No linked news activity found for this company.